Celltex News
ChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells. Celltex is continuing to monitor and participate in this effective research.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to info@celltexbank.com. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
The Difference Between Cord Blood Banking and Adult Stem Cell Banking
Cord blood banking is a relatively well-known concept, especially among new or soon-to-be parents. While it does have potential benefits, there may be some confusion about which cells are stored and how they may be used.
In this article, we explore the key differences between cord blood banking and adult stem cell banking.
Read MoreMesenchymal Stem Cells vs Exosomes: A Comparison Summary from the Celltex Scientific Team
Written and reviewed by the Celltex Scientific Team, this article summarizes the similarities and differences between MSC therapy and therapies that utilize extracellular vesicles (primarily exosomes).
Read More